awmsg logo



nelarabine (Atriance®)


Reference No. 216

Publication date:
11/06/2009


Appraisal information

nelarabine (Atriance®) 5 mg/ml solution for infusion


Company: GlaxoSmithKline
BNF category: Malignant disease and immunosupression
NMG meeting date: 25/03/2009
AWMSG meeting date: 29/04/2009
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0909
Ministerial ratification: 10/06/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Nelarabine (Atriance®) is recommended for restricted use within NHS Wales for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to, or has relapsed, following treatment with at least two chemotherapy regimens. Treatment should be restricted to patients in whom there is an intention to proceed to allogeneic stem cell transplantation, as it is not cost effective when used for palliation. Nelarabine (Atriance®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download